<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-11-18" updated="2019-12-02">
  <drugbank-id primary="true">DB05786</drugbank-id>
  <drugbank-id>DB11733</drugbank-id>
  <name>Irofulven</name>
  <description>A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. &#13;
&#13;
MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.</description>
  <cas-number>158440-71-2</cas-number>
  <unii>6B799IH05A</unii>
  <average-mass>246.3016</average-mass>
  <monoisotopic-mass>246.125594442</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3774</ref-id>
        <pubmed-id>10637489</pubmed-id>
        <citation>Kelner MJ, McMorris TC, Estes L, Samson KM, Trani NA, MacDonald JR: Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia. 2000 Jan;14(1):136-41.</citation>
      </article>
      <article>
        <ref-id>A3775</ref-id>
        <pubmed-id>12231547</pubmed-id>
        <citation>Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ: Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res. 2002 Sep;8(9):3000-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells.  Once inside the cells, the compound binds to DNA and protein targets.  This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or “cell suicide.”  During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as cyclohexenones. These are compounds containing a cylohexenone moiety, which is a six-membered aliphatic ring that carries a ketone and has one endocyclic double bond.</description>
    <direct-parent>Cyclohexenones</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Carbonyl compounds</subclass>
    <alternative-parent>Acyloins</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Tertiary alcohols</alternative-parent>
    <substituent>Acyloin</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Cyclohexenone</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Tertiary alcohol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">6-hydroxymethylacylfulvene</synonym>
    <synonym language="english" coder="">HMAF</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Irofulven</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alkylating Drugs</category>
      <mesh-id>D000477</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents, Alkylating</category>
      <mesh-id>D018906</mesh-id>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>Radiation-Sensitizing Agents</category>
      <mesh-id>D011838</mesh-id>
    </category>
    <category>
      <category>Terpenes</category>
      <mesh-id>D013729</mesh-id>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Irofulven.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Irofulven.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Irofulven.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Irofulven.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.19</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.20e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.67</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(6'R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-6',7'-dihydrospiro[cyclopropane-1,5'-indene]-7'-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>irofulven</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>246.3016</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>246.125594442</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C15H18O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NICJCIQSJJKZAH-AWEZNQCLSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>57.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>70.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>27.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-1.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>135002</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>148189</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175427030</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>130640</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50410835</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Irofulven</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL118218</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0003422</id>
      <name>Far upstream element-binding protein 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q96AE4" source="Swiss-Prot">
        <name>Far upstream element-binding protein 1</name>
        <general-function>Transcriptional activator activity, rna polymerase ii distal enhancer sequence-specific binding</general-function>
        <specific-function>Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription.</specific-function>
        <gene-name>FUBP1</gene-name>
        <locus>1p31.1</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.71</theoretical-pi>
        <molecular-weight>67560.205</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4004</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FUBP1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U05040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q96AE4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FUBP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>DNA helicase V</synonym>
          <synonym>FBP</synonym>
          <synonym>hDH V</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006677|Far upstream element-binding protein 1
MADYSTVPPPSSGSAGGGGGGGGGGGVNDAFKDALQRARQIAAKIGGDAGTSLNSNDYGY
GGQKRPLEDGDQPDAKKVAPQNDSFGTQLPPMHQQQSRSVMTEEYKVPDGMVGFIIGRGG
EQISRIQQESGCKIQIAPDSGGLPERSCMLTGTPESVQSAKRLLDQIVEKGRPAPGFHHG
DGPGNAVQEIMIPASKAGLVIGKGGETIKQLQERAGVKMVMIQDGPQNTGADKPLRITGD
PYKVQQAKEMVLELIRDQGGFREVRNEYGSRIGGNEGIDVPIPRFAVGIVIGRNGEMIKK
IQNDAGVRIQFKPDDGTTPERIAQITGPPDRCQHAAEIITDLLRSVQAGNPGGPGPGGRG
RGRGQGNWNMGPPGGLQEFNFIVPTGKTGLIIGKGGETIKSISQQSGARIELQRNPPPNA
DPNMKLFTIRGTPQQIDYARQLIEEKIGGPVNPLGPPVPHGPHGVPGPHGPPGPPGPGTP
MGPYNPAPYNPGPPGPAPHGPPAPYAPQGWGNAYPHWQQQAPPDPAKAGTDPNSAAWAAY
YAHYYQQQAQPPPAAPAGAPTTTQTNGQGDQQNPAPAGQVDYTKAWEEYYKKMGQAVPAP
TGAPPGGQPDYSAAWAEYYRQQAAYYAQTSPQGMPQHPPAPQGQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012396|Far upstream element-binding protein 1 (FUBP1)
ATGGCAGACTATTCAACAGTGCCTCCCCCCTCTTCTGGCTCAGCTGGTGGCGGTGGTGGC
GGCGGTGGTGGTGGAGGAGTTAACGACGCTTTCAAAGATGCACTGCAGAGAGCCCGGCAG
ATTGCAGCAAAAATTGGAGGTGATGCAGGGACATCACTGAATTCAAATGACTATGGTTAT
GGGGGACAAAAAAGACCTTTAGAAGATGGAGATGGCTCTTGGACAAGTCCGAGCAGTACA
ACACACTGGGAGGGAATGCCCTCTCCTTTTAAAGATCAACCAGATGCTAAGAAAGTTGCT
CCTCAAAATGACTCTTTTGGAACACAGTTACCACCGATGCATCAGCAGCAAAGCAGATCT
GTAATGACAGAAGAATACAAAGTTCCAGATGGAATGGTTGGATTCATAATTGGCAGAGGA
GGTGAACAGATCTCACGCATACAACAGGAATCTGGATGCAAAATACAGATAGCTCCTGAC
AGTGGTGGCCTTCCAGAAAGGTCCTGTATGTTAACTGGAACACCTGAATCTGTCCAGTCA
GCAAAACGGTTACTGGACCAGATTGTTGAAAAAGGAAGACCAGCTCCTGGCTTCCATCAT
GGCGATGGACCGGGAAATGCAGTTCAAGAAATCATGATTCCAGCTAGCAAGGCAGGATTA
GTCATTGGAAAAGGGGGAGAAACTATTAAACAGCTTCAGGAACGGGCTGGAGTTAAAATG
GTTATGATTCAAGACGGGCCGCAGAACACTGGTGCTGACAAACCTCTTAGGATTACAGGA
GACCCATATAAAGTTCAACAAGCCAAGGAAATGGTGTTAGAGTTAATTCGTGATCAAGGC
GGTTTCAGAGAAGTTCGGAATGAGTATGGGTCAAGAATAGGAGGAAATGAAGGGATAGAT
GTCCCCATTCCAAGATTTGCTGTTGGCATTGTAATAGGAAGAAATGGAGAGATGATCAAA
AAAATACAAAATGATGCTGGTGTTCGCATTCAGTTTAAGCCAGATGATGGGACAACACCC
GAAAGGATAGCACAAATAACAGGACCTCCAGACCGATGTCAACATGCTGCAGAAATTATT
ACAGACCTTCTTCGAAGTGTTCAGGCTGGTAATCCTGGTGGACCTGGACCTGGTGGTCGA
GGAAGAGGTAGAGGTCAAGGCAACTGGAACATGGGACCACCTGGTGGACTACAGGAATTT
AATTTTATTGTGCCAACTGGGAAAACTGGATTAATAATAGGAAAAGGAGGTGAAACCATA
AAAAGCATAAGCCAGCAGTCTGGTGCAAGAATAGAACTTCAGAGAAATCCTCCACCAAAT
GCAGATCCTAATATGAAGTTATTTACAATTCGTGGCACTCCACAACAGATAGACTATGCT
CGGCAACTCATAGAAGAAAAGATTGGTGGCCCAGTAAATCCTTTAGGGCCACCTGTACCC
CATGGGCCCCATGGTGTCCCAGGCCCCCATGGACCTCCTGGGCCTCCAGGGCCTGGAACT
CCAATGGGACCATACAACCCTGCACCTTATAATCCTGGACCACCAGGCCCGGCTCCTCAT
GGTCCTCCAGCCCCATATGCTCCCCAGGGATGGGGAAATGCATATCCACACTGGCAGCAG
CAGGCTCCTCCTGATCCAGCTAAGGCAGGAACGGATCCAAATTCAGCAGCTTGGGCTGCT
TATTACGCTCACTATTATCAACAGCAAGCACAGCCACCACCAGCAGCCCCTGCAGGTGCA
CCAACTACAACTCAAACTAATGGACAAGGAGATCAGCAGAATCCAGCCCCAGCTGGACAG
GTTGATTATACCAAGGCTTGGGAAGAGTACTACAAGAAAATGGGTCAGGCAGTTCCTGCT
CCGACTGGGGCTCCTCCAGGTGGTCAGCCAGATTATAGTGCAGCCTGGGCTGAGTATTAT
AGACAACAAGCAGCCTATTATGCCCAGACAAGTCCCCAGGGAATGCCACAGCATCCTCCA
GCACCTCAGGGCCAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF09005</identifier>
            <name>DUF1897</name>
          </pfam>
          <pfam>
            <identifier>PF00013</identifier>
            <name>KH_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>poly(A) RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>single-stranded DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase II promoter</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>